# DUR Committee

April 20th, 2012 Minutes

**Members Present:**
Robert Carlson, MD
John Pappenheim, MD
Jenny Love, MD, MPH.
Mary-Beth Gardner, ANP
McCormick, William, Pharm.D.
Julie Pritchard, Pharm.D. (Magellan)
Erin Narus, Pharm.D. (Magellan)
C.J. Kim, R.Ph (DHSS)

**Members Absent:**
Dharna Begich, Pharm.D.

**Public attendees**:
None

- Meeting started at 1:06pm and roll call.
- Review of minutes from previous meeting. (Approved)
- Review agenda for additions:
  - Dr. Pappenheim asked for Naltrexone PA to be added for review. (Approved)

**ProDUR**

- CNS stimulants – Proposed Quantity Limits/Dose Optimization:
  - CJ Kim presented on stimulant medications. Covering topics such as reducing fraud, waste, abuse, diversion, stockpiling and overall use in general. Presented overview of current system and background information of claims and recipients. Initially from February meeting only proposed a few medications for specific quantity limits, then re-proposed the entire class to prevent shifting from one medication with a quantity limit to another medication without a quantity limit. From February meeting, members wanted additional information breakdown usage by recipient age groups and a comparison what other states currently are using for their Quantity Limits.
  - Bill McCormick inquired about quantity limits during drug shortages; Julie noted that the call center had a 'quick check' ; specifically a clause known times of drug shortages that the call center can review and use a override to allow for doubling a lower dose that may exceed the quantity limits.
  - Committee discussed options of during titration then using dose optimization. Magellan suggested a possibility of a 'Rolling Quantity Limits' but the notifications that the prescriber would need were not plausible. Of the low-dose stimulants amended, the Department will review a 9-month usage and present to committee of findings.
  - Quantity limits were good; but for the process of titration and stabilizing a patient may take more time and dose variation; need more flexibility built into the quantity limits to be less intrusive to pharmacy and practitioner. (See Below, as committee addressed some of their concerns)
  - Addressing medication titration and quantity limits:
    - Amend Adderall Tablets quantity limits; 5mg and 7.5mg to 120 tablets. (Aid in titration)
    - Amend Adderall XR Capsules quantity limits; 5mg and 10mg to 60 capsules. (Aid in titration)
    - Amend Dextroamphetamine tablets; 5mg to 120 tablets.
    - Amend Focalin Tablets; 2.5mg and 5mg to 90 tablets. (Aid in titration)
    - Amend Focalin XR Capsules; 5mg and 10mg to 60 capsules. (Aid in titration)
    - Amend Methylphenidate tablets; 5mg and 10mg to 120 tablets. (Aid in titration)
      - UNAMIOUNSLY APPROVED WITH THE ABOVE AMENDMENTS.
- New Prescription medications (Medications that have been on the Interim Prior Authorization list for a minimum of six months):

- C.Kim presented information and claim details for (6) medications on the list
    - Departments Recommendations list, UNAMIOUNSLY APPROVED.
    - Approved Nucynta ER Quantity Limits (2 per day), UNAMIOUNSLY APPROVED.

- Dr. Pappenheim presented on naltrexone and background of the PA criteria that may not be suitable since its inception and intent versus current usage.
    - UNAMIOUNSLY APPROVED to Remove Naltrexone from Prior Authorization.

**Retrospective DUR**

- Discuss review criteria
- Retrospective DUR (FDA Alert: Medication Guides required to alert patients to possible cardiovascular and psychiatric risks with ADHD drug products).
    - The profiles were discussed and evaluated for intervention letters to be sent out to the providers.
- Dr. Carlson added suggestion for Department to construct an informative introduction sheet to aid new members.
- Thanked Dr. Carlson for all his Outstanding contribution to the DUR as his 2nd 3-year term expires in June 2012.
- Next meeting is scheduled for September 21, 2012 and location TBD.
- Meeting adjourned 3:00pm.